Macrophage migration inhibitory factor promotes cell death and aggravates neurologic deficits after experimental stroke.
Multiple mechanisms contribute to tissue demise and functional recovery after stroke. We studied the involvement of macrophage migration inhibitory factor (MIF) in cell death and development of neurologic deficits after experimental stroke. Macrophage migration inhibitory factor is upregulated in the brain after cerebral ischemia, and disruption of the Mif gene in mice leads to a smaller infarct volume and better sensory-motor function after transient middle cerebral artery occlusion (tMCAo). In mice subjected to tMCAo, we found that MIF accumulates in neurons of the peri-infarct region, particularly in cortical parvalbumin-positive interneurons. Likewise, in cultured cortical neurons exposed to oxygen and glucose deprivation, MIF levels increase, and inhibition of MIF by (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid methyl ester (ISO-1) protects against cell death. Deletion of MIF in Mif(-/-) mice does not affect interleukin-1β protein levels in the brain and serum after tMCAo. Furthermore, disruption of the Mif gene in mice does not affect CD68, but it is associated with higher galectin-3 immunoreactivity in the brain after tMCAo, suggesting that MIF affects the molecular/cellular composition of the macrophages/microglia response after experimental stroke. We conclude that MIF promotes neuronal death and aggravates neurologic deficits after experimental stroke, which implicates MIF in the pathogenesis of neuronal injury after stroke.
Department of Clinical Sciences, Laboratory for Experimental Brain Research, Lund University, Lund, Sweden. ana.inacio@med.lu.se
Ana R
AR
Inácio
Karsten
K
Ruscher
Lin
L
Leng
Richard
R
Bucala
Tomas
T
Deierborg
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D015214:Antigens, Differentiation, Myelomonocytic / Q000378:metabolism; D015153:Blotting, Western; D016923:Cell Death / Q000187:drug effects*; D002478:Cells, Cultured; D002560:Cerebrovascular Circulation / Q000502:physiology; D037502:Galectin 3 / Q000378:metabolism; D005947:Glucose / Q000172:deficiency; D002534:Hypoxia, Brain / Q000473:pathology; D007150:Immunohistochemistry; D020244:Infarction, Middle Cerebral Artery / Q000473:pathology; D053583:Interleukin-1beta / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008263:Macrophage Migration-Inhibitory Factors / Q000235:genetics / Q000502:physiology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009422:Nervous System Diseases / Q000209:etiology* / Q000523:psychology*; D009474:Neurons / Q000378:metabolism; D010320:Parvalbumins / Q000378:metabolism; D004856:Postural Balance / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D020521:Stroke / Q000150:complications* / Q000523:psychology*; D014162:Transfection; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D037502:Galectin 3; D005947:Glucose; D053583:Interleukin-1beta; D007770:L-Lactate Dehydrogenase; D008263:Macrophage Migration-Inhibitory Factors; D010320:Parvalbumins; C081026:CD68 protein, mouse; D000097382:CD68 Molecule